Mr. David Regan reports

SONA NANOTECH TO HOLD INVESTOR WEBINAR TO DISCUSS FOLLOW-UP DATA FROM FIRST-IN-HUMAN CANCER THERAPY STUDY

Sona Nanotech Inc. will host an investor webinar on Wednesday, March 18, 2026, at 3:30 p.m. ET, to discuss follow-up data from its first-in-human study of its Targeted Hyperthermia therapy (THT), which resulted the generation of immune responses in eight out of 10 treated and biopsied tumours, with complete responses seen in six out of 10. Interested parties can register for this webinar on-line.

Joining on the webinar will be the study's principal investigator, Dr. Carlos Rojas, executive director of the Centro de Investigacion Clinica, Bradford Hill, along with Sona's chief executive officer, David Regan, and chief medical officer, Dr. Carman Giacomantonio. Data to be presented will include patient follow-up assessments, including evidence that THT treatments generated a clinical response in secondary, untreated tumours, known as an abscopal effect, in a study patient. This study of 10, late-stage melanoma patients who had failed on standard-of-care immunotherapy protocols, was undertaken to assess the safety, tolerability and efficacy of THT in humans.

David Regan, Sona's CEO, commented: "We are excited to be able to share our perspectives on some follow-up data from our first-in-human study from the principal investigator. While the study was intended to assess THT's safety, tolerability and ability to prime tumours for further treatment, THT given as a monotherapy treatment demonstrated in an astounding 80 per cent clinical response rate (CRR), with 60 per cent of treated, biopsied tumours cleared in only two weeks. In particular, evidence of an abscopal effect will be discussed with an opportunity for participants to question the study's principal investigator."

A recording of the webinar will be made available following the webinar in the investor information section of the company's website.

About Sona Nanotech Inc.

Sona Nanotech is developing Targeted Hyperthermia, a photothermal cancer therapy, which uses therapeutic heat to treat solid cancer tumours. The heat is delivered to tumours by infrared light that is absorbed by Sona's gold nanorods in the tumour and re-emitted as heat. Therapeutic heat (42 C to 48 C) stimulates the immune system, shrinks tumours, inactivates cancer stem cells and increases tumour perfusion -- thus enabling drugs to reach all tumour compartments more effectively. Targeted Hyperthermia promises to be safe, effective, minimally invasive, competitive in cost, and a valuable adjunct to drug therapy and other cancer treatments.

Sona has developed multiple proprietary methods for the manufacture of gold nanoparticles, which it uses for the development of both cancer therapies and diagnostic testing platforms. Sona Nanotech's gold nanorod particles are cetyltrimethylammonium (CTAB) free, eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications.

We seek Safe Harbor.